Omeros Newsroom

D. Boral Capital Initiates Omeros(OMER.US) With Buy Rating, Announces Target Price $36

Moomoo NewsDec 23, 2024 07:33 ET

Omeros Initiated at Buy by D. Boral Capital

Dow JonesDec 23, 2024 07:19 ET

D. Boral Capital Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $36

BenzingaDec 23, 2024 07:07 ET

Needham Maintains Omeros(OMER.US) With Hold Rating

Moomoo NewsDec 20, 2024 13:44 ET

Omeros (OMER) Gets a Hold From Needham

TipRanksDec 20, 2024 12:55 ET

Rodman & Renshaw Maintains Omeros(OMER.US) With Buy Rating, Cuts Target Price to $9

Moomoo NewsNov 14, 2024 07:32 ET

Rodman & Renshaw Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $9

BenzingaNov 14, 2024 06:54 ET

Needham Maintains Omeros(OMER.US) With Hold Rating

Moomoo NewsNov 14, 2024 05:33 ET

Omeros Analyst Ratings

BenzingaNov 14, 2024 05:25 ET

Omeros Analyst Ratings

BenzingaJun 4, 2024 05:47 ET

Omeros Analyst Ratings

BenzingaMay 16, 2024 06:42 ET

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)

TipRanksMay 16, 2024 06:36 ET

Omeros (OMER) Gets a Hold From Needham

TipRanksMay 16, 2024 06:30 ET

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)

TipRanksApr 9, 2024 07:45 ET

Omeros Analyst Ratings

BenzingaNov 10, 2023 15:44 ET

Omeros' Clinical Trials Setbacks and Financial Standing Lead to Underperform Rating: An Analysis

TipRanksOct 16, 2023 18:55 ET

UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating

MT NewswiresMar 15, 2023 11:15 ET

Bank of America Securities Keeps Their Sell Rating on Omeros (OMER)

TipRanksMar 14, 2023 06:47 ET

Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and SAGE Therapeutics (SAGE)

TipRanksFeb 7, 2023 07:07 ET

Needham Reaffirms Their Hold Rating on Omeros (OMER)

TipRanksFeb 6, 2023 11:56 ET